Management Team

For the past two decades, Paul has established lasting relationships with key business leaders and stakeholders in Japan and the U.S., particularly in the Life Sciences field. He has completed transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals and Gilead.

He has also provided financial leadership and business development for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales. Throughout his tenure, he structured and closed major transactions that brought high-value products to the Japanese pharmaceutical market. Additionally, his other corporate responsibilities included overall evaluation of corporate asset values for purposes of divestiture or acquisition. Paul subsequently cofounded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., that is now one of Japan’s most successful orphan drug companies. As President of the U.S. division and a cofounder, he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.

As an adult-onset Type 1 diabetic, he knows firsthand how a patient can struggle to get the right diagnosis and treatment. Only 40,000 adults a year are diagnosed with Type 1 diabetes. Paul is actively involved in the Juvenile Diabetes Research Foundation (JDRF), an organization funding research for Type 1 diabetes.

I Richard Garr, J.D., was a Director, and Neuralstem’s Chief Executive Officer and President from 1996 through February of 2016. Additionally, as a co-founder and General Counsel at Neuralstem, Mr. Garr had responsibility and oversight for all operations of a world-leading regenerative medicine company developing cell and gene therapies, small molecule drugs and genomic database products. He was responsible for worldwide business development, joint ventures, and licensing, a worldwide intellectual property portfolio and among other firsts created the stem cell industry’s first development agreements for Korea, Indonesia, Singapore, Malaysia, and Vietnam.

In 2016, Mr. Garr became a full-time advocate for patient’s rights to access experimental treatments in development both in the U.S. and Europe. In 2018, he founded Access Hope CRO, the only CRO dedicated exclusively to facilitating safe, ethical, and legal expanded patient access to potentially life-saving investigational treatments under the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2018. Mr. Garr is a graduate of Drew University (1976) and the Columbus School of Law, The Catholic University of America (1979).

Additionally, he was a founder and is a current Board member of the First Star Institute, a children’s charity focused on abused children’s issues; a founder of The Starlight Foundation Mid-Atlantic chapter, which focuses on helping seriously ill children; and a past Honorary Chairman of the Brain Tumor Society.

Dr. Barry A. Ginsberg is an accomplished professional who advises executives across industries, bringing expertise in strategy and performance in the pharmaceuticals and medical-products sector. He also consults with healthcare companies to develop global strategies and operating models and is an experienced leader with a demonstrated history of success working as an entrepreneur in the health and wellness industry. He is skilled in comprehensive eye care which includes the diagnosis, treatment, management, and prevention of diseases of the eye and visual system. Dr. Ginsberg has also participated in new Ophthalmic Drug and Procedure development trials utilizing his vast patient database.

Combined with an extensive network of contacts and an exclusive key opinion leader database throughout North America, Europe, Middle East, Asia, and South America, he brings consummate value to the team.

Dr. Ginsberg earned his Bachelor’s of Arts degree in Chemistry with a minor in Economics from Yeshiva University, and his Bachelor’s of Science and Doctorate degrees from the Pennsylvania College of Optometry. Concurrently, he attended the LaSalle College MBA Program in Philadelphia. He participated in four Externships including the Feinbloom Low Vision Center in Philadelphia, focusing on age-related macular degeneration (AMD) and the Goldschleger Eye Institute in Tel Hashomer Hospital in Israel, focusing on diseases of the eye including glaucoma.

Dr. Ginsberg’s community service participation included the Flying Samaritans and One Sight. He recently retired after practicing over 35 years in the medical field.

Ronald Bordens is an accomplished executive scientist with over 40 years of successful experience in biotechnology and pharmaceutical industries for companies focused on research and development.

He possesses a unique skill set including but not limited to people leadership, scientific expertise, and quality assurance and control. His pharmaceutical industry experience includes drug discovery, drug development and research technology with a focus on bioanalytical research, biomarkers, and leadership development during his 26-year career at Schering-Plough Research.

Dr. Sohn is President of Sohn Health Strategies and Adjunct Professor at the University of California, San Francisco, her alma mater, where she received her Doctor of Pharmacy degree and the Distinguished Alumnus Award (2000). Dr. Sohn is currently Chairman of BioEclipse Therapeutics, a privately held, clinical-stage oncology company and is an independent Director on the Board of Directors of Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Rubius Therapeutics (NASDAQ: RUBY), Axcella Health (NASDAQ: AXLA), Landec Corp (NASDAQ: LNDC) and privately held Maze Therapeutics.

Dr. Sohn has deep biopharmaceutical industry knowledge with over thirty years of U.S. and global experience, and a reputation as a strategic thinker with the ability to drive a strong interface between research & development and marketing. Her expertise includes the development and introduction of new medicines for patients and diseases with significant unmet needs. Her skill sets include strategic product development, business development and the introduction of new vaccines, pharmaceutical products and consumer healthcare brands.

Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee. Subsequently, she led the US commercialization of the company’s largest CNS product. Dr. Sohn later became senior vice president, Worldwide Business Development and a member of the global executive committee at GlaxoSmithKline Consumer Healthcare where she led U.S. and global transactions, including the $1.3 billion acquisition and integration of Block Drug and the $566 million acquisition of CNS, Inc. Before that, she was Vice President Worldwide Strategic Product Development for the cardiovascular, pulmonary and metabolic therapeutic areas at SmithKline Beecham Pharmaceuticals responsible for portfolio prioritizations and overseeing the global launch of Coreg for congestive heart failure which became a $1 billion indication.